Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.

Abstract

Multicentric Castleman disease (MCD) is an uncommon lymphoproliferative disorder for which the best therapeutic option is not yet well established. Immune-related disorders are rare complications of MCD. We report on an MCD case in a 23-year-old patient with extensive abdominal involvement and associated immune hemolytic anemia and Raynaud phenomenon. He was negative for human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8). After 8 courses of the anti-CD20 monoclonal antibody (rituximab), the patient achieved complete remission. Interestingly, Raynaud phenomenon disappeared under treatment and no new hemolytic events occurred. Anti-CD20 antibody treatment could be an attractive therapeutic approach for MCD, mainly when immune-related disorders are associated.

• Authors: Enrique M Ocio, Fermin M Sanchez-Guijo, Maria Diez-Campelo, Cristina Castilla, Oscar J Blanco, Dolores Caballero, Jesus F San Miguel
• Journal: American journal of hematology (Am J Hematol) Vol. 78 Issue 4 Pg. 302-5 (Apr 2005) ISSN: 0361-8609 [Print] United States
• PMID: 15795923 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Rituximab

Topics

• Adult
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents (therapeutic use)
• Castleman Disease (diagnostic imaging, drug therapy, pathology)
• Humans
• Lymph Nodes (diagnostic imaging, pathology)
• Male
• Rituximab
• Tomography, X-Ray Computed
• Treatment Outcome